Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Two-Part, Open-label Study in Healthy Adult Volunteers to Assess a Single Dose of Vadadustat as a Victim in Drug-Drug Interactions With Cyclosporine, Probenecid and Rifampin

Trial Profile

A Phase 1, Two-Part, Open-label Study in Healthy Adult Volunteers to Assess a Single Dose of Vadadustat as a Victim in Drug-Drug Interactions With Cyclosporine, Probenecid and Rifampin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Probenecid (Primary) ; Rifampicin (Primary) ; Vadadustat (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Akebia Therapeutics

Most Recent Events

  • 25 Mar 2021 According to an Akebia Therapeutics media release, data from this trial will be presented at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21),
  • 28 Mar 2019 Last check against ClinicalTrials.gov: US National Institutes of Health
  • 20 Mar 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top